# Natera

Signatera 已针对多种癌症获得欧盟 IVDR 认证，在肌层浸润性膀胱癌中获 FDA 伴随诊断批准，获 NCCN 指南推荐用于膀胱癌 ctDNA-MRD 检测，并已广泛临床推出超灵敏的 Signatera Genome MRD 检测。

Source: https://cn.bioecon.ru/companies/natera/
Updated: 2026-07-20

- 国家: United States
- 代码: NTRA

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 认证 | Signatera在多种癌症领域持有欧盟IVDR C类认证 | https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx, https://www.natera.com/company/news/natera-announces-ivdr-certification-for-signatera-across-multiple-cancers/ |
| 监管批准 | Signatera获FDA伴随诊断批准,用于肌层浸润性膀胱癌 | https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx, https://investor.natera.com/news/news-details/2026/Signatera-CDx-Approved-by-the-FDA-as-a-Companion-Diagnostic-in-Muscle-Invasive-Bladder-Cancer-MIBC/default.aspx, https://www.natera.com/company/news/natera-reports-second-quarter-2026-financial-results/, https://www.natera.com/company/news/nccn-recommends-ctdna-mrd-testing-using-signatera-technology-in-landmark-bladder-cancer-guideline-update/ |
| 监管批准 | 在日本获PMDA批准用于结直肠癌 | https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx, https://www.natera.com/company/news/natera-announces-ivdr-certification-for-signatera-across-multiple-cancers/ |
| 生产基地 | 实验室位于德克萨斯州奥斯汀、加利福尼亚州圣卡洛斯，以及科罗拉多州博尔德（子公司） | https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/ |
| 产能 | 奥斯汀扩建旨在拥有全球最大的测序能力 | https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/ |
| 营收 | 2025年为$2,306.1 million | https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm |
| 营收 | 2026年营收指引为$27.4亿至$28.2亿 | https://investor.natera.com/news/news-details/2026/Natera-Reports-First-Quarter-2026-Financial-Results/default.aspx |
| 员工人数 | 预计通过奥斯汀扩建创造最多400个新就业岗位 | https://investor.natera.com/news/news-details/2026/Natera-Reports-First-Quarter-2026-Financial-Results/default.aspx, https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/, https://www.natera.com/company/news/natera-reports-second-quarter-2026-financial-results/ |

独立来源: sec.gov

## 技术

- [液体活检与 ctDNA 诊断](https://cn.bioecon.ru/technology/liquid-biopsy-ctdna-diagnostics/)